EQL Pharma Management

Management Kriterienprüfungen 3/4

EQL Pharma CEO ist Axel Schorling , ernannt in Aug 2022, hat eine Amtszeit von 2.25 Jahren. Die jährliche Gesamtvergütung beträgt SEK2.26M , bestehend aus 72.6% Gehalt und 27.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.07% der Aktien des Unternehmens, im Wert von SEK21.58M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.3 Jahre bzw. 4.8 Jahre.

Wichtige Informationen

Axel Schorling

Geschäftsführender

SEK 2.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts72.6%
Amtszeit als Geschäftsführer2.3yrs
Eigentum des Geschäftsführers1.1%
Durchschnittliche Amtszeit des Managements2.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder4.8yrs

Jüngste Management Updates

Recent updates

Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Nov 27
Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Axel Schorling im Vergleich zu den Einnahmen von EQL Pharma verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

SEK 31m

Jun 30 2024n/an/a

SEK 26m

Mar 31 2024SEK 2mSEK 2m

SEK 23m

Vergütung im Vergleich zum Markt: AxelDie Gesamtvergütung ($USD205.64K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Swedish ($USD467.92K).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Axel mit der Unternehmensleistung zu vergleichen.


Geschäftsführer

Axel Schorling (38 yo)

2.3yrs

Amtszeit

SEK 2,262,000

Vergütung

Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Christer Fahraeus
Founder & Chairman18.8yrsSEK 250.00kkeine Daten
Axel Schorling
President & CEO2.3yrsSEK 2.26m1.07%
SEK 21.6m
Anna Jonsson
Chief Financial Officer2.9yrskeine Daten0.047%
SEK 952.8k
Martin Kristofferson
Chief Operating Officer2.3yrskeine Daten0.070%
SEK 1.4m
Alexander Brising
Chief Commercial Officerno datakeine Daten0.88%
SEK 17.8m
Carl Lindgren
Chief Business Development Officer1.7yrskeine Datenkeine Daten

2.3yrs

Durchschnittliche Betriebszugehörigkeit

50yo

Durchschnittliches Alter

Erfahrenes Management: EQLDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Christer Fahraeus
Founder & Chairman18.8yrsSEK 250.00kkeine Daten
Linda Neckmar
Independent Director4.8yrsSEK 100.00k0.0086%
SEK 173.5k
Anders Mansson
Independent Director6.3yrsSEK 100.00k0.034%
SEK 694.1k
Per Svangren
Independent Director3.8yrsSEK 100.00k0.034%
SEK 694.1k
Per Ollermark
Independent Director3.8yrsSEK 100.00kkeine Daten

4.8yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrener Vorstand: EQLDie Vorstandsmitglieder gelten als erfahren (4.8 Jahre durchschnittliche Amtszeit).